RxDoctor Payments Data

Mihoko Fujita, MD

Radiation Oncology · Washington, DCNPI 1447295746

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.2% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for radiation oncology clinicians in DC, where the typical reported total is $804.

$271in general payments, 2019–2025

Across 15 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tesaro, Inc.$62
  • E.r. Squibb & Sons, L.L.C.$31
  • Takeda Pharmaceuticals U.S.A., Inc.$24
  • AstraZeneca$22
  • Bristol Myers Squibb$21
  • Bayer$20
  • plus $90 from 6 others

What the payments were for

  • Food & beverage$25594%
  • Education$166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$271 in reported general payments places this provider in the 45th percentile of 25 radiation oncology providers in District of Columbia.

See all radiation oncology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$85,399
Medicare patients
100
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ondansetron Hcl12$119

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →